Nasdaq:US$20.17 (-0.79) | HKEX:HK$31.70 (-1.70) | AIM:£3.24 (-0.13)
上一篇文章   |   下一篇文章
公告及新聞稿, 其他業務, 新聞稿 | 2014-10-01

Chi-Med and Merck Serono sign co-promotion agreement

Press Release – 

London: Wednesday, 1 October 2014: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Chi-Med, through its subsidiary Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited (“Hutchison Sinopharm”), has signed a co-promotion agreement with Merck Serono Co., Ltd. (“Merck Serono”) a subsidiary of Merck in China to market certain cardiovascular prescription drug products in China.

Hutchison Sinopharm will exclusively co-promote Merck Serono’s Bisoprolol Fumarate tablets, under the Concor® trademark, in several provinces in China. Concor® is a major brand in the beta-blocker sub-segment of the cardiovascular prescription drug market in China.

Chi-Med today operates a commercial network in China of approximately 1,600 cardiovascular market focused medical sales representatives, covering more than 13,000 hospitals, through its joint ventures, Shanghai Hutchison Pharmaceuticals Limited and Hutchison Sinopharm.



    Christian Hogg, CEO

Telephone:      +852 2121 8200

Panmure Gordon (UK) Limited
    Richard Gray
    Andrew Potts

Telephone:      +44 20 7886 2500 

Citigate Dewe Rogerson

    Anthony Carlisle

    David Dible

Telephone:      +44 20 7638 9571

Mobile:             +44 7973 611 888

Mobile:             +44 7967 566 919


About Chi-Med

 Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.  Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.  Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.  Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

 Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13).  For more information, please visit:


About Merck Serono China

 With over 1,300 employees and a nationwide presence, Merck Serono is dedicated to serving the Chinese market. Merck Serono currently markets 15 products in 8 therapeutic areas in China. Merck Serono China is No.1 in fertility and thyroid therapeutic areas, and has strong presence in cardiovascular, endocrinology, oncology and NDD diseases.